Adverse Events and Clinical Outcomes in Patients Treated with PD-(L)1 Blockade for Advanced Non-Small-Cell Lung Cancer

References

• Siegel RL , MillerKD, FuchsHE, JemalA. Cancer statistics, 2021.CA Cancer J. Clin.71(1), 7–33 (2021).
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration . Oncology (cancer)/hematologic malignancies approval notifications (2022). www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications (Accessed 7April2022).
   Google Scholar
• National Comprehensive Cancer Network (NCCN) . NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer (2022). www.nccn.org/guidelines/guidelines-detail?category=1&id=1450 (Accessed 15September2022).
   Google Scholar
• Mencoboni M , CeppiM, BruzzoneMet al. Effectiveness and safety of immune checkpoint inhibitors for patients with advanced non small-cell lung cancer in real-world: review and meta-analysis. Cancers (Basel) 13(6), 1388 (2021).
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb . Study of nivolumab (BMS-936558) in patients with advanced or metastatic squamous cell nonsmall-cell lung cancer who have received at least 2 prior systemic regimens (2021). ( NLM Identifier: NCT01721759). https://clinicaltrials.gov/ct2/show/NCT01721759 (Accessed 23May2022).
   Google Scholar
• Hoffman-La Roche . A randomized phase 2 study of atezolizumab (an engineered anti-PDL1 antibody) compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy – ‘POPLAR’ (2019). ( NLM Identifier: NCT01903993). http://clinicaltrials.gov/show/NCT01903993 (Accessed 8April2022).
   Google Scholar
• Merck Sharp & Dohme Corp . Study of two doses of pembrolizumab (MK-3475) versus docetaxel in previously treated participants with non-small cell lung cancer (MK-3475-010/KEYNOTE-010) (2021). ( NLM Identifier: NCT01905657). https://clinicaltrials.gov/ct2/show/NCT01905657 (Accessed 23May2022).
   Google Scholar
• Wang P-F , ChenY, SongS-Yet al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 8, 730 (2017).
   PubMed Web of Science ®Google Scholar
• Puzanov I , DiabA, AbdallahKet al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5(1), 95 (2017).
   PubMed Web of Science ®Google Scholar
• Arbour KC , MezquitaL, LongNet al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J. Clin. Oncol. 36(28), 2872–2878 (2018).
   PubMed Web of Science ®Google Scholar
• Fuca G , GalliG, PoggiMet al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open 4(1), e000457 (2019).
   PubMed Web of Science ®Google Scholar
• Petrelli F , SignorelliD, GhidiniMet al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel) 12(3), 546 (2020).
   PubMed Web of Science ®Google Scholar
• Bernal GM , MezquitaL, AuclinEet al. Baseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. Ann. Oncol. 28(Suppl. 5), v472 (2017).
   Google Scholar
• Scott SC , PennellNA. Early use of systematic corticosteroids in patients with advanced NSCLC treated with nivolumab.J. Thorac. Oncol.13(11), 1771–1775 (2018).
   PubMed Web of Science ®Google Scholar
• Zhou X , YaoZ, YangHet al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 18(1), 87 (2020).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention . Chronic obstructive pulmonary disease among adults – United States, 2011.MMWR Morb. Mortal. Wkly Rep.61(46), 938–943 (2012).
   PubMedGoogle Scholar
• Simeone JC , NordstromBL, PatelK, KleinAB. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting.Future Oncol.15(30), 3491–3502 (2019).
   PubMed Web of Science ®Google Scholar
• George S , BellEJ, ZhengYet al. The impact of adverse events on health care resource utilization, costs, and mortality among patients treated with immune checkpoint inhibitors. Oncologist 26(7), e1205–e1215 (2021).
   PubMed Web of Science ®Google Scholar
• Connell CM , RabyS, BehIet al. Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes. Ann. Oncol. 28(7), 1678–1679 (2017).
   PubMed Web of Science ®Google Scholar
• Della Corte CM , MorgilloF. Early use of steroids affects immune cells and impairs immunotherapy efficacy.ESMO Open4(1), e000477 (2019).
   PubMed Web of Science ®Google Scholar
• Skribek M , RounisK, AfsharSet al. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Eur. J. Cancer 145, 245–254 (2021).
   PubMed Web of Science ®Google Scholar
• Hosmer DW , LemeshowS, MayS. Applied Survival Analysis: Regression Modeling of Time to Event Data (2nd Edition). Wiley Interscience, NJ, USA (2008). https://onlinelibrary.wiley.com/doi/book/10.1002/9780470258019
   Google Scholar
• Anderson JR , CainKC, GelberRD. Analysis of survival by tumor response.J. Clin. Oncol.1(11), 710–719 (1983).
   PubMed Web of Science ®Google Scholar
• Brahmer JR , LacchettiC, SchneiderBJet al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 36(17), 1714–1768 (2018).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology (NCCN Guidelines®): management of immunotherapy-related toxicities. Version 3.2021 (2021). https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf
   Google Scholar
• Maillet D , CorbauxP, StelmesJJet al. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. Eur. J. Cancer 132, 61–70 (2020).
   PubMed Web of Science ®Google Scholar